Nanoplatforms for Delivery of Inhibitors and Biologics
- Technology Benefits
- The nanoparticle formulation:ΓÇóInvolves use of biocompatible componentsΓÇóEffectively minimizes toxicity of individual componentsΓÇóMaximizes accumulation of therapeutic agents at the diseased siteΓÇóIs highly injectable as compared to existing formulationsΓÇóIs capable of being used as a mono-therapy or a dual drug deliveryΓÇóIs designed to target a tumor using passive or active methodsΓÇóIs further capable of being used in combination with chemo and radio therapiesΓÇóHas an increased bioavailability as compared to conventional platformsΓÇóWould be commercially useful for treatment of various indications such as cancer, neurological disorders, traumatic brain injuries, CNS disorders, inflammation, urinary tract disorders, and respiratory system disorders
- Detailed Technology Description
- None
- *Abstract
-
In prior art, many available drugs (such as PARP inhibitors) are difficult to deliver using existing platforms/delivery mechanisms. Moreover, such drugs are available only in oral formulations that are associated with poor bioavailability. Some of the other key limitations associated with existing formulations are insufficient accumulation at the target site as well as undesirable side effects. This invention discloses a novel, nanoparticle based formulation for delivery of therapeutic agents and/or inhibitors that are otherwise difficult to deliver.
- *Principal Investigator
-
Name: Srinivas Sridhar
Department:
Name: Shifalika Tangutoori
Department:
- Country/Region
- USA
For more information, please click Here
